Literature DB >> 28105664

Visceral and somatic pain modalities reveal NaV 1.7-independent visceral nociceptive pathways.

James R F Hockley1, Rafael González-Cano2, Sheridan McMurray1, Miguel A Tejada-Giraldez2, Cian McGuire3, Antonio Torres4, Anna L Wilbrey1, Vincent Cibert-Goton3, Francisco R Nieto2, Thomas Pitcher1, Charles H Knowles3, José Manuel Baeyens2, John N Wood5, Wendy J Winchester1, David C Bulmer3, Cruz Miguel Cendán2, Gordon McMurray1.   

Abstract

KEY POINTS: Voltage-gated sodium channels play a fundamental role in determining neuronal excitability. Specifically, voltage-gated sodium channel subtype NaV 1.7 is required for sensing acute and inflammatory somatic pain in mice and humans but its significance in pain originating from the viscera is unknown. Using comparative behavioural models evoking somatic and visceral pain pathways, we identify the requirement for NaV 1.7 in regulating somatic (noxious heat pain threshold) but not in visceral pain signalling. These results enable us to better understand the mechanisms underlying the transduction of noxious stimuli from the viscera, suggest that the investigation of pain pathways should be undertaken in a modality-specific manner and help to direct drug discovery efforts towards novel visceral analgesics. ABSTRACT: Voltage-gated sodium channel NaV 1.7 is required for acute and inflammatory pain in mice and humans but its significance for visceral pain is unknown. Here we examine the role of NaV 1.7 in visceral pain processing and the development of referred hyperalgesia using a conditional nociceptor-specific NaV 1.7 knockout mouse (NaV 1.7Nav1.8 ) and selective small-molecule NaV 1.7 antagonist PF-5198007. NaV 1.7Nav1.8 mice showed normal nociceptive behaviours in response to intracolonic application of either capsaicin or mustard oil, stimuli known to evoke sustained nociceptor activity and sensitization following tissue damage, respectively. Normal responses following induction of cystitis by cyclophosphamide were also observed in both NaV 1.7Nav1.8 and littermate controls. Loss, or blockade, of NaV 1.7 did not affect afferent responses to noxious mechanical and chemical stimuli in nerve-gut preparations in mouse, or following antagonism of NaV 1.7 in resected human appendix stimulated by noxious distending pressures. However, expression analysis of voltage-gated sodium channel α subunits revealed NaV 1.7 mRNA transcripts in nearly all retrogradely labelled colonic neurons, suggesting redundancy in function. By contrast, using comparative somatic behavioural models we identify that genetic deletion of NaV 1.7 (in NaV 1.8-expressing neurons) regulates noxious heat pain threshold and that this can be recapitulated by the selective NaV 1.7 antagonist PF-5198007. Our data demonstrate that NaV 1.7 (in NaV 1.8-expressing neurons) contributes to defined pain pathways in a modality-dependent manner, modulating somatic noxious heat pain, but is not required for visceral pain processing, and advocate that pharmacological block of NaV 1.7 alone in the viscera may be insufficient in targeting chronic visceral pain.
© 2017 The Authors. The Journal of Physiology © 2017 The Physiological Society.

Entities:  

Keywords:  NaV1.7; colorectal; heat pain; visceral nociception; visceral pain; voltage gated sodium channel

Mesh:

Substances:

Year:  2017        PMID: 28105664      PMCID: PMC5390874          DOI: 10.1113/JP272837

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  58 in total

1.  What activates visceral afferents?

Authors:  D Grundy
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

2.  Characterization of neurons responsive to noxious colorectal distension in the T13-L2 spinal cord of the rat.

Authors:  T J Ness; G F Gebhart
Journal:  J Neurophysiol       Date:  1988-10       Impact factor: 2.714

3.  Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.

Authors:  R Rolke; R Baron; C Maier; T R Tölle; - D R Treede; A Beyer; A Binder; N Birbaumer; F Birklein; I C Bötefür; S Braune; H Flor; V Huge; R Klug; G B Landwehrmeyer; W Magerl; C Maihöfner; C Rolko; C Schaub; A Scherens; T Sprenger; M Valet; B Wasserka
Journal:  Pain       Date:  2006-05-11       Impact factor: 6.961

Review 4.  Genetics and phenotyping of urological chronic pelvic pain syndrome.

Authors:  Jordan Dimitrakov; David Guthrie
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

5.  An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways.

Authors:  Jennifer R Deuis; Katharina Zimmermann; Andrej A Romanovsky; Lourival D Possani; Peter J Cabot; Richard J Lewis; Irina Vetter
Journal:  Pain       Date:  2013-05-24       Impact factor: 6.961

6.  Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

Authors:  H Mertz; B Naliboff; J Munakata; N Niazi; E A Mayer
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

7.  P2Y Receptors Sensitize Mouse and Human Colonic Nociceptors.

Authors:  James R F Hockley; Michael M Tranter; Cian McGuire; George Boundouki; Vincent Cibert-Goton; Mohamed A Thaha; L Ashley Blackshaw; Gregory J Michael; Mark D Baker; Charles H Knowles; Wendy J Winchester; David C Bulmer
Journal:  J Neurosci       Date:  2016-02-24       Impact factor: 6.167

8.  An SCN9A channelopathy causes congenital inability to experience pain.

Authors:  James J Cox; Frank Reimann; Adeline K Nicholas; Gemma Thornton; Emma Roberts; Kelly Springell; Gulshan Karbani; Hussain Jafri; Jovaria Mannan; Yasmin Raashid; Lihadh Al-Gazali; Henan Hamamy; Enza Maria Valente; Shaun Gorman; Richard Williams; Duncan P McHale; John N Wood; Fiona M Gribble; C Geoffrey Woods
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

9.  SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes.

Authors:  Caroline R Fertleman; Mark D Baker; Keith A Parker; Sarah Moffatt; Frances V Elmslie; Bjarke Abrahamsen; Johan Ostman; Norbert Klugbauer; John N Wood; R Mark Gardiner; Michele Rees
Journal:  Neuron       Date:  2006-12-07       Impact factor: 17.173

10.  Pain without nociceptors? Nav1.7-independent pain mechanisms.

Authors:  Michael S Minett; Sarah Falk; Sonia Santana-Varela; Yury D Bogdanov; Mohammed A Nassar; Anne-Marie Heegaard; John N Wood
Journal:  Cell Rep       Date:  2014-01-16       Impact factor: 9.423

View more
  22 in total

Review 1.  The physiological function of different voltage-gated sodium channels in pain.

Authors:  George Goodwin; Stephen B McMahon
Journal:  Nat Rev Neurosci       Date:  2021-03-29       Impact factor: 34.870

Review 2.  Combining Human and Rodent Genetics to Identify New Analgesics.

Authors:  Alban Latremoliere; Michael Costigan
Journal:  Neurosci Bull       Date:  2017-07-01       Impact factor: 5.203

Review 3.  Voltage-gated sodium channels: (NaV )igating the field to determine their contribution to visceral nociception.

Authors:  Andelain Erickson; Annemie Deiteren; Andrea M Harrington; Sonia Garcia-Caraballo; Joel Castro; Ashlee Caldwell; Luke Grundy; Stuart M Brierley
Journal:  J Physiol       Date:  2018-02-06       Impact factor: 5.182

4.  Stimulus intensity-dependent recruitment of NaV1 subunits in action potential initiation in nerve terminals of vagal C-fibers innervating the esophagus.

Authors:  Fei Ru; Nikoleta Pavelkova; Jeffrey L Krajewski; Jeff S McDermott; Bradley J Undem; Marian Kollarik
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-07-29       Impact factor: 4.052

5.  Pharmacological Inhibition of the Voltage-Gated Sodium Channel NaV1.7 Alleviates Chronic Visceral Pain in a Rodent Model of Irritable Bowel Syndrome.

Authors:  Yan Jiang; Joel Castro; Linda V Blomster; Akello J Agwa; Jessica Maddern; Gudrun Schober; Volker Herzig; Chun Yuen Chow; Fernanda C Cardoso; Paula Demétrio De Souza França; Junior Gonzales; Christina I Schroeder; Steffen Esche; Thomas Reiner; Stuart M Brierley; Glenn F King
Journal:  ACS Pharmacol Transl Sci       Date:  2021-06-07

6.  Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain.

Authors:  Liberty François-Moutal; Erik T Dustrude; Yue Wang; Tatiana Brustovetsky; Angie Dorame; Weina Ju; Aubin Moutal; Samantha Perez-Miller; Nickolay Brustovetsky; Vijay Gokhale; May Khanna; Rajesh Khanna
Journal:  Pain       Date:  2018-10       Impact factor: 7.926

Review 7.  Advances in understanding nociception and neuropathic pain.

Authors:  Ewan St John Smith
Journal:  J Neurol       Date:  2017-10-14       Impact factor: 4.849

8.  Effects of Tetrodotoxin in Mouse Models of Visceral Pain.

Authors:  Rafael González-Cano; Miguel Ángel Tejada; Antonia Artacho-Cordón; Francisco Rafael Nieto; José Manuel Entrena; John N Wood; Cruz Miguel Cendán
Journal:  Mar Drugs       Date:  2017-06-21       Impact factor: 5.118

9.  Up-Down Reader: An Open Source Program for Efficiently Processing 50% von Frey Thresholds.

Authors:  Rafael Gonzalez-Cano; Bruno Boivin; Daniel Bullock; Laura Cornelissen; Nick Andrews; Michael Costigan
Journal:  Front Pharmacol       Date:  2018-05-01       Impact factor: 5.810

10.  Characterization of Synthetic Tf2 as a NaV1.3 Selective Pharmacological Probe.

Authors:  Mathilde R Israel; Thomas S Dash; Stefanie N Bothe; Samuel D Robinson; Jennifer R Deuis; David J Craik; Angelika Lampert; Irina Vetter; Thomas Durek
Journal:  Biomedicines       Date:  2020-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.